PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)
02 nov. 2023 08h30 HE
|
PaxMedica, Inc.
TARRYTOWN, N.Y., Nov. 02, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, has...
Groundbreaking study reveals link between air pollution and incidence of Parkinson’s disease
31 oct. 2023 18h07 HE
|
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
Phoenix, Oct. 31, 2023 (GLOBE NEWSWIRE) -- A new study led by researchers at Barrow Neurological Institute has found that people living in regions with median levels of air pollution have a 56...
Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults
30 oct. 2023 08h30 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics Phase 1a Clinical Data Presented at Clinical Trials on Alzheimer's Disease Meeting Support Continued Clinical Development
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
30 oct. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Embolization Coils Market revenue to cross USD 3 Billion by 2035, says Research Nester
26 oct. 2023 06h30 HE
|
Research Nester
New York , Oct. 26, 2023 (GLOBE NEWSWIRE) -- The global embolization coils market size is estimated to attain at 6% CAGR from 2023 to 2035. The market is expected to garner a revenue of USD 3...
Alzheimer’s Leaders Discuss How to Shift Science into Clinical Practice During National Alzheimer’s Summit
20 oct. 2023 12h58 HE
|
UsAgainstAlzheimer's
Washington, DC, Oct. 20, 2023 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s this week hosted the 2023 National Alzheimer’s Summit, a groundbreaking event dedicated to applying recent scientific and...
Allyx Therapeutics to Present Phase 1 Data for Lead Compound ALX-001 at the 16th Clinical Trials on Alzheimer's Disease Meeting
19 oct. 2023 16h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics presents Phase 1 ALX-001 data at CTAD. ALX-001 is a small molecule with unique mechanism at mGluR5 to protect and preserve synapses.
Neurovascular Devices Market - Global Forecast to 2028: Increasing Incidence of Ischemic Stroke and Cerebral Aneurysms Boosts Demand
18 oct. 2023 05h48 HE
|
Research and Markets
Dublin, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The "Neurovascular Devices Market by Disease Pathology (Cerebral Ameurysm (Embolic coils), Ischemic Stroke (Clot retrievers, Aspiration, Microcatheters),...
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
10 oct. 2023 02h30 HE
|
Sosei Group Corporation
The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry...
"Advancements in Acute Ischemic Stroke Therapeutics Market CAGR of 4.6 %: A Ray of Hope for Stroke Patients", Says Market.us
25 sept. 2023 09h03 HE
|
Market.Us
New York, Sept. 25, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Acute Ischemic Stroke Therapeutics Market size is expected to be worth around USD 14.0 Billion by...